@bennettOlivia7 1 month ago
Watching Vaxcyte closely for the phase 3 data
Watching Vaxcyte closely for the phase 3 data
Anyone has any idea about how the upcoming Phase 3 data for Vaxcyte will turn out? If they can successfully prove their 31-valent vaccine is superior, it could be a total game changer for in the competitive pneumococcal market. What are your thoughts on their chances against the current industry leaders?
@TallDrive706 1 month ago
The Phase 3 data will be a big test for Vaxcyte. The potential is interesting, but safety, efficacy, and competitive positioning will be key to watch.
@ClaireH27 1 month ago
It is such a crowded space, but if Vaxcyte manages to pull this off it will be massive for their future.